RT Journal Article
SR Electronic
T1 Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.02.20084673
DO 10.1101/2020.05.02.20084673
A1 Patterson, Bruce K.
A1 Seethamraju, Harish
A1 Dhody, Kush
A1 Corley, Michael J.
A1 Kazempour, Kazem
A1 Lalezari, Jay
A1 Pang, Alina P.S.
A1 Sugai, Christopher
A1 Francisco, Edgar B.
A1 Pise, Amruta
A1 Rodrigues, Hallison
A1 Ryou, Mathew
A1 Wu, Helen L.
A1 Webb, Gabriela M.
A1 Park, Byung S.
A1 Kelly, Scott
A1 Pourhassan, Nader
A1 Lelic, Alena
A1 Kdouh, Lama
A1 Herrera, Monica
A1 Hall, Eric
A1 Aklin, Enver
A1 Ndhlovu, Lishomwa C.
A1 Sacha, Jonah B.
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.05.02.20084673.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is now pandemic with nearly three million cases reported to date1. Although the majority of COVID-19 patients experience only mild or moderate symptoms, a subset will progress to severe disease with pneumonia and acute respiratory distress syndrome (ARDS) requiring mechanical ventilation2. Emerging results indicate a dysregulated immune response characterized by runaway inflammation, including cytokine release syndrome (CRS), as the major driver of pathology in severe COVID-193,4. With no treatments currently approved for COVID-19, therapeutics to prevent or treat the excessive inflammation in severe disease caused by SARS-CoV-2 infection are urgently needed. Here, in 10 terminally-ill, critical COVID-19 patients we report profound elevation of plasma IL-6 and CCL5 (RANTES), decreased CD8+ T cell levels, and SARS-CoV-2 plasma viremia. Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia. Consistent with reduction of plasma IL-6, single-cell RNA-sequencing revealed declines in transcriptomic myeloid cell clusters expressing IL-6 and interferon-related genes. These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19.Competing Interest StatementDr. Sacha has received compensation for consulting for CytoDyn Inc., a company that may have a commercial interest in the results of this research. The potential conflict of interest has been reviewed and managed by Oregon Health Sciences University. Drs. Kelly and Pourhassan are employees of CytoDyn Inc., owner and developer of Leronlimab and Dr. Lalezari is a principal investigator for CytoDyn Inc. through his company Quest Clinical Research. Dr. Patterson, Brian Francisco, Amruta Pise, Matthew Ryou, Hallison Rodrigues are employees of IncellDx, Inc., a diagnostic company providing assays to Cytodyn Inc. Dr. Ndhlovu has received compensation for serving on a scientific advisory board for Abbvie. Lama Kdouh and Alina Lelic are employees of Beckman Coulter Life Sciences, and Monica Herrera and Eric Hall are employees of Bio-Rad, Inc. Drs. Kush Dhody and Kazem Kazempour are employees of Amarex Clinical Research, LLC, a company that manages clinical trials and regulatory matters for CytoDyn Inc.Funding Statementno external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll primary data presented in this study are available from the corresponding author upon reasonable request. Primary data exists for all figures.